Evidence map›Paper›PMID 38139359›Full record

ArticleInternational journal of molecular sciences2023

Akt Is Controlled by Bag5 through a Monoubiquitination to Polyubiquitination Switch.

Ismael Bracho-Valdés, Rodolfo Daniel Cervantes-Villagrana, Yarely Mabell Beltrán-Navarro, Adán Olguín-Olguín, Estanislao Escobar-Islas, Jorge Carretero-Ortega, J Alberto Olivares-Reyes, Guadalupe Reyes-Cruz, J Silvio Gutkind, José Vázquez-Prado

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ismael Bracho-ValdésDepartment of Pharmacology, Cinvestav-IPN. Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Mexico City 07360, Mexico.ORCID 0000-0003-3582-6489
Rodolfo Daniel Cervantes-VillagranaDepartment of Pharmacology, Cinvestav-IPN. Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Mexico City 07360, Mexico.ORCID 0000-0002-6599-7994
Yarely Mabell Beltrán-NavarroDepartment of Pharmacology, Cinvestav-IPN. Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Mexico City 07360, Mexico.
Adán Olguín-OlguínDepartment of Pharmacology, Cinvestav-IPN. Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Mexico City 07360, Mexico.
Estanislao Escobar-IslasDepartment of Pharmacology, Cinvestav-IPN. Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Mexico City 07360, Mexico.
Jorge Carretero-OrtegaDepartment of Pharmacology, Cinvestav-IPN. Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Mexico City 07360, Mexico.
J Alberto Olivares-ReyesDepartment of Biochemistry, Cinvestav-IPN. Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Mexico City 07360, Mexico.ORCID 0000-0001-8389-9274
Guadalupe Reyes-CruzDepartment of Cell Biology, Cinvestav-IPN. Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Mexico City 07360, Mexico.
J Silvio GutkindDepartment of Pharmacology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, San Diego, CA 92093, USA.
José Vázquez-PradoDepartment of Pharmacology, Cinvestav-IPN. Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Mexico City 07360, Mexico.ORCID 0000-0001-5797-6643
Instituto Politécnico Nacional · MXUniversity of California San Diego · USUniversidad Autónoma de Guadalajara · MX

Funding

Consejo Nacional de Humanidades, Ciencias y Tecnologías FOP16 grant No. 319283 (to J.V-P.)Consejo Nacional de Humanidades, Ciencias y Tecnologías FORDECYT-PRONACES grant No. 1794 (to G.R-C.)
6 · The paper itself

Abstract

The serine-threonine kinase Akt plays a fundamental role in cell survival, metabolism, proliferation, and migration. To keep these essential processes under control, Akt activity and stability must be tightly regulated; otherwise, life-threatening conditions might prevail. Although it is well understood that phosphorylation regulates Akt activity, much remains to be known about how its stability is maintained. Here, we characterize BAG5, a chaperone regulator, as a novel Akt-interactor and substrate that attenuates Akt stability together with Hsp70. BAG5 switches monoubiquitination to polyubiquitination of Akt and increases its degradation caused by Hsp90 inhibition and Hsp70 overexpression. Akt interacts with BAG5 at the linker region that joins the first and second BAG domains and phosphorylates the first BAG domain. The Akt-BAG5 complex is formed in serum-starved conditions and dissociates in response to HGF, coincident with BAG5 phosphorylation. BAG5 knockdown attenuated Akt degradation and facilitated its activation, whereas the opposite effect was caused by BAG5 overexpression. Altogether, our results indicate that Akt stability and signaling are dynamically regulated by BAG5, depending on growth factor availability.

Indexed as

Molecular ChaperonesProto-Oncogene Proteins c-aktAdaptor Proteins, Signal TransducingAnimalsHEK293 CellsHSP70 Heat-Shock ProteinsHumansMicePhosphorylationUbiquitinationAdaptor Proteins, Signal TransducingBAG5 protein, humanBAG5 protein, mouseHSP70 Heat-Shock ProteinsMolecular ChaperonesProto-Oncogene Proteins c-aktAktBAG-5Bcl-2 associated athanogene 5Hsp70ubiquitin-dependent degradation

Identifiers

PMID38139359
PMCPMC10743781
OpenAlexW4389794805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.